Articul8 launches Bivia to bring domain-specific decision intelligence to enterprise AI agents Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
Funding and support provided by Bill & Melinda Gates Foundation Study will focus on determining…
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
BREXAFEMME, an oral, non-azole medication, is the first and only FDA-approved therapy for both the…
Carrick Therapeutics Announces $35 Million Investment from Pfizer
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
Carrick Therapeutics Announces $35 Million Investment from Pfizer
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for…
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Kura Oncology to Host Investor Event on December 10, 2022
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH…
Kura Oncology to Host Investor Event on December 10, 2022
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH…
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company”…
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company”…
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product Development MORRISVILLE, N.C.,…
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product Development MORRISVILLE, N.C.,…
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all…
Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
clonoSEQ is the first and only MRD test in DLBCL with Medicare coverage across all…
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)
BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…